image description

Tag: anifrolumab

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] Read More

Positive Results on Anifrolumab for Lupus Published in New England Journal of Medicine

December 18, 2019 The Lupus Research Alliance (LRA) welcomes additional positive results published today in the New England Journal of Medicine online edition from AstraZeneca’s Phase 3 TULIP-2 trial studying the investigational biologic anifrolumab as a treatment for systemic lupus erythematosus (SLE or lupus).  The new study provides further details showing that anifrolumab, which targets […] Read More

Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting

November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] Read More

Important Message from CEO Kenneth Farber: U.S. FDA Approves New Lupus Treatment

August 2, 2021 Dear Friend of the Lupus Research Alliance, As we reported this morning, the lupus community has much to celebrate with the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (brand name, Saphnelo™). As a first-in-class and only new treatment for systemic lupus erythematosus in a decade, this approval marks a major […] Read More

Lupus Research Lifted Up in Everyday Health

May 27, 2021 Funding innovative research year-round is the most meaningful way the Lupus Research Alliance Lifts Up Lupus with the promise of better treatments and one day a cure. This excellent article in EVERYDAY HEALTH reports on eight of the most important discoveries in lupus of the past year, virtually all of which got […] Read More

Promising New Lupus Treatments Highlighted ACR Annual Meeting

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […] Read More

LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020

30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […] Read More

LRA Welcomes Positive Results with Anifrolumab for Reducing Lupus Flares

May 13, 2021 A new study analyzing data from two large clinical trials showed that the investigational therapy anifrolumab reduced flares in people with moderate to severe lupus while allowing lowered steroid use. The study was published in the professional journal Lupus by top lupus researchers, several of whom are leaders in the Lupus Clinical […] Read More

LRA-Supported Study Discovers How Harmful Immune Cells Develop

August 17, 2020 In a new study published in the journal Immunity, Lupus Research Alliance-funded researcher Dr. Boris Reizis and his colleagues identified conditions under which immune cells called B cells begin to attack healthy genetic material (DNA). Dr. Reizis’ findings highlight the potential of drugs such as anifrolumab and BIIB-059 as potential treatments for […] Read More

Promising News from Major Medical Meeting, EULAR

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates